Nouvelle déclaration d'incident
No de la demande: 2022-1688
Numéro de référence du titulaire d'homologation: 2022-CA-000034
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: CANADA
État: NEWFOUNDLAND
ARLA No d'homologation 30735 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Hartz UltraGuard Flea and Tick Drops for Dogs Over 28 kg
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Non
Propriétaire de l'animal
Cat / Chat
Persian/Domestic Shorthair crossbred
1
Femme
2
Inconnu
Cutanée
Unknown / Inconnu
>8 hrs <=24 hrs / > 8 h < = 24 h
Système
Unknown / Inconnu
Non
Non
Unknown/Inconnu
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 13-Feb-2022, a 2 year old, neutered, female, Persian/Domestic Shorthair crossbred cat, of unknown weight, in unknown condition, with concomitant medical condition of fleas, was administered 1 drop of Hartz UltraGuard Flea and Tick Drops for Dogs Over 28 kg (Phenothrin (Sumithrin)) via the topical route by the animal owner. This was an extra label use as the product is not intended for use on cats. Approximately 10 hours post application, the cat developed shaking. The cat was not evaluated by a veterinarian, no treatments were performed, and the clinical sign continued. Immediate veterinary intervention was recommended. Follow-up was attempted but no further information was received.
Modérée
Assessment: Application of concentrated pyrethroids to cats can result in neurologic signs including severe muscle tremors and seizures. This was a misuse of product. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.